Gentian is a Norway based, international company working on global solutions that change health care. With in-house production, R&D and marketing, Gentian serves the global market for diagnostic tests with sensitive biochemical products developed by leveraging proprietary, disruptive, diagnostic technologies. Current and pipeline products contribute to improved diagnostics and cost reductions in treatment of kidneys, inflammation, cardiovascular diseases, cancer and viral infections.
On 14th December, 2016, Gentian was admitted to the Oslo Stock Exhange list ‘Merkur Markets’. The Gentian Diagnostics AS ticker is GENT-ME.
See Gentian’s statements in NewsPoint here
For further investor relations information, please contact firstname.lastname@example.org